DexCom, Inc. (DXCM): Price and Financial Metrics


DexCom, Inc. (DXCM)

Today's Latest Price: $408.36 USD

6.18 (1.54%)

Updated Sep 30 3:25pm

Add DXCM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 140 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

DXCM Stock Summary

  • With a market capitalization of $38,505,600,811, Dexcom Inc has a greater market value than 95.07% of US stocks.
  • DXCM's current price/earnings ratio is 188.11, which is higher than 96.29% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for DXCM is currently 97.68, higher than 96.7% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to DXCM, based on their financial statements, market capitalization, and price volatility, are ANSS, YNDX, ILMN, NTES, and Z.
  • Visit DXCM's SEC page to see the company's official filings. To visit the company's web site, go to www.dexcom.com.
DXCM Daily Price Range
DXCM 52-Week Price Range

DXCM Stock Price Chart Technical Analysis Charts


DXCM Price/Volume Stats

Current price $408.36 52-week high $456.23
Prev. close $402.18 52-week low $145.23
Day low $397.51 Volume 368,656
Day high $415.63 Avg. volume 1,271,227
50-day MA $416.85 Dividend yield N/A
200-day MA $335.49 Market Cap 39.10B

DexCom, Inc. (DXCM) Company Bio


DexCom focuses on the design, development, and commercialization of continuous glucose monitoring systems for patients with diabetes. The company was founded in 1999 and is based in San Diego, California.

DXCM Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$408.36$377.37 -6%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dexcom Inc. To summarize, we found that Dexcom Inc ranked in the 43th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 5.5%. In terms of the factors that were most noteworthy in this DCF analysis for DXCM, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 96. Its equity weight surpasses that of 74.82% of free cash flow generating stocks in the Healthcare sector.
  • The company's compound free cash flow growth rate over the past 5.42 years comes in at 0.85%; that's greater than 88.87% of US stocks we're applying DCF forecasting to.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 13.37% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-8%
1%-7%
2%-6%
3%-5%
4%-4%
5%-3%

HBIO, ITGR, CNC, IART, and PRAH can be thought of as valuation peers to DXCM, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about Dexcom Inc that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

SAN DIEGO--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

Business Wire | September 22, 2020

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

SAN DIEGO--(BUSINESS WIRE)--Dexcom announces first-ever registry dedicated to tracking outcomes of in-hospital real-time CGM use in response to the COVID-19 pandemic

Business Wire | September 16, 2020

Dexcom Appoints Karen Dahut to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Karen Dahut to Board of Directors

Business Wire | August 12, 2020

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Conference Presentation

Business Wire | August 10, 2020

Exact Sciences A Better Near-Term Capital Gain Buy Than DexCom Inc.

Investment Thesis Exact Sciences Corporation (EXAS) and DexCom, Inc. (DXCM) are active investment alternatives in competition with dozens of other medical diagnostic and research enterprises. Success from an investment point of view relates more to increased stock price than lives saved. That measure depends importantly on a combination of research...

Peter F. Way, CFA on Seeking Alpha | August 3, 2020

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo -4.01%
3-mo 0.25%
6-mo 56.61%
1-year 174.34%
3-year 734.67%
5-year 370.95%
YTD 86.69%
2019 82.59%
2018 108.75%
2017 -3.87%
2016 -27.11%
2015 48.77%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7499 seconds.